OBJECTIVE：To compare the efficacy and safety of  rosuvastatin and atorvastatin in the treatment of coronary heart disease. METHODS： 96 patients with coronary heart disease were randomly divided into observation group and control group. All patients received  reasonable diet control， low molecular weight heparin， Aspirin enteric-coated tablet， β-blockers， nitric acid lipids and other conventional treatment， but no vitamins and other antioxidant drugs. Based on it， observation group was orally given 10 mg Rosuvastatin tablet， once a day； control group was given 20 mg Atorvastatin capsule， once a day. The treatment course for both groups was 6 months. Clinical efficacy， total cholesterol （TC）， triglyceride （TG）， low density lipoprotein cholesterol （LDL-C）， high density lipoprotein cholesterol （HDL-C）， high-sensitivity C-reactive protein （hs-CRP） and left ventricular ejection fraction （LVEF） before and after treatment， and the incidence of adverse reactions in 2 groups were observed. RESULTS： There were no significant differences in the total effective rate and incidence of adverse reactions between 2 groups（P＞0.05）. Before treatment， there were no significant differences in the TC，TG，LDL-C，HDL-C，hs-CRP and  LVEF between 2 groups（P＞0.05）. After treatment，TC，TG，LDL-C，HDL-C and hs-CRP in 2 groups were significantly lower than before， and TC， LDL-C and hs-CRP in observation group were lower than control group， HDL-C and LVEF in 2 groups were significantly higher than before， and observation group was higher than control group， the differences were statistically significant （P＜0.05）. CONCLUSIONS： Rosuvastatin and atorvastatin has similar efficacy and safety in the treatment of coronary heart disease， but rosuvastatin is superior to atorvastatin in terms of reducing lipid levels.